Prognosis of Covid-19 on its 1st Anniversary: Global v/s indian Scenario

Author:

Biradar S M.1ORCID,Kohima B.1ORCID,Mulimani M S.2,Nayak Vishwanath1ORCID,Warad Vijayakumar2ORCID,Jugati Avinash2,Hunasagi B S.1,Pathi Indu1,M Chetankumar1ORCID,Awasthi Santhosh R.1ORCID,V Basavaraj1,Hawaldar yoti1

Affiliation:

1. 1Department of PharmD (Doctor of Pharmacy), SSM College of Pharmacy and Research Centre, Vijaypura, Karnataka, India

2. 2Department of General Medicine, Shri B M. Patil Medical College Hospital and Research Centre, Vijaypura Karnataka, India

Abstract

Corona virus disease 2019 (Covid-19) is an acute respiratory illness caused by the Corona virus. Corona virus 2 (SARS-CoV-2) is a continuing global health crisis that has harmed the physiological and psychological health of people in over 200 countries worldwide. The current study performed a narrative review of its origin, epidemiology, transmission, clinical parameters, effects on mental health, management, vaccines and their trails, and future perspectives. The ease with which humans may transmit information to one another is unnoticeable in the early stages, making COVID-19 both terrifying and remarkable, but as time progresses, it can be managed successfully with the available therapies to some extent. Based on the condition and co-morbidities, therapeutic management is used in the pandemic situation, which includes drugs like antivirals, chloroquine and hydroxychloroquine, convalescent plasma therapy, Azithromycin, Corticosteroids, Cytokine’s, and oxygen therapy. Strategies such as self-quarantine, social isolation, and 70-day nationwide and state-by-state lockdowns in India aided in slowing the virus's spread, which may have been catastrophic otherwise. However, there are no clinically approved safer vaccines until the end of 2020. Several businesses have taken the lead in producing COVID-19 vaccines and came up with vaccines like Pfizer, Moderna from the US and UK, Covaxin, and Covishield from India, and vaccination programs began in India for targeting more than 300 million people.

Publisher

Oriental Scientific Publishing Company

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3